Clinical Research Directory

Inclusion Criteria: * Male or female \>30 and \<80 years old. * Has a body mass index \>25 and \<45 kg/m2. * Previously diagnosed with prediabetes and/or T2D. * If not previously diagnosed, has a fasting blood glucose ≥ 100 mg/dL and/or HbA1c ≥ 5.7% Exclusion Criteria: * Morbidly obese patients (BMI \>45 kg/m2) and lean patients (BMI \<25 kg/m2) * Evidence of type 1 diabetes and diabetics requiring insulin therapy. * Subjects who have not been weight stable (\>2 kg weight change in past 3 months) * Subjects who have been recently active (\>30 min of moderate/high intensity exercise, 3 times/week). * Subjects who are smokers or who have quit smoking \<1 years ago * Subjects with abnormal estimated glomerular filtration rate (eGFR). * Hypertriglyceridemic (\>400 mg/dl) and hypercholesterolemic (\>260 mg/dl) subjects * Hypertensive (\>160/100 mmHg) * Subjects with a history of significant metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with, alter the outcome measures, or impact subject safety. * Pregnant (as evidenced by positive urine pregnancy test) or nursing women. * Subjects with contraindications to participation in an exercise training program * Currently taking active weight suppression medication (e.g. phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzphetamine, diethylpropion, phendimetrazine) * Known hypersensitivity to perflutren (contained in Definity)